+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asia-Pacific Cancer Vaccines Market - Growth, Trends, and Forecasts (2020 - 2025)

  • PDF Icon


  • 70 Pages
  • August 2020
  • Region: Asia Pacific
  • Mordor Intelligence
  • ID: 5175746
Certain factors that are driving the market's growth include the increasing burden of cancer cases and technological developments in cancer vaccines. The incidence of cancer is increasing every year and it has been the major factor for the growth of the cancer vaccines market.

According to Glocbocan, in 2018, there were around 774,323 new cases of lung cancer, which contributed around 18% of total cancer cases in China. Cancer damages the immune system, as cancer cells produce self-antigen. The cancer vaccines play a vital role in the maintenance of the immune system, as they are considered to be biological response modifiers. These cancer vaccines target the infectious agents that may cause cancer, through the production of the antibodies. Cancer vaccines are considered to be a new therapy and are not popular, as compared to the other alternative therapeutic drugs. The cancer vaccines have shown great potential in both preventive and therapeutic ways.

Hence, owing to the aforementioned factors, the market for cancer vaccines is expected to grow at a high rate, during the forecast period.

Key Market Trends

Preventive Vaccines is Expected to Show Better Growth Over the Forecast Period.

Preventive vaccines or prophylactic vaccines are the vaccines intended to prevent cancer in healthy people. These vaccines work by preventing infectious agents that cause or contribute to the development of cancer. These vaccines are similar to traditional vaccines that help prevent infectious diseases, such as polio and measles, by protecting the body against infections. Most of the preventive vaccines stimulate the production of antibodies, which bind to specifically targeted microbes and block their ability to cause infection. Hence, owing to these factors, along with the rising burden of cancer, the market is expected to witness significant growth over the forecast period.

Competitive Landscape

The majority of cancer vaccines is being manufactured by the global key players. Market leaders with more funds for research and a better distribution system have established their position in the market. This has helped the market grow.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Cancer
4.2.2 Emphasis on Early Diagnosis of Cancer
4.2.3 Technological Developments in Cancer Vaccines
4.3 Market Restraints
4.3.1 Presence of Alternative Therapies
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Technology
5.1.1 Recombinant Cancer Vaccines
5.1.2 Whole-cell Cancer Vaccines
5.1.3 Viral Vector and DNA Cancer Vaccines
5.1.4 Other Technologies
5.2 By Treatment Method
5.2.1 Preventive Vaccine
5.2.2 Therapeutic Vaccine
5.3 By Application
5.3.1 Prostate Cancer
5.3.2 Cervical Cancer
5.3.3 Other Applications
5.4 Geography
5.4.1 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
6.1 Company Profiles
6.1.1 Astellas Pharma Inc.
6.1.2 AstraZeneca Plc
6.1.3 Glaxosmithkline Plc
6.1.4 Merck & Co., Inc.
6.1.5 Pfizer Inc.
6.1.6 Sanofi
6.1.7 Bristol-Myers Squibb

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Glaxosmithkline Plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi
  • Bristol-Myers Squibb